Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes

• Status: Terminated
• Trial end date: 2014-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of ISIS ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects with Type 2 Diabetes on stable treatment with metformin.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ionis Pharmaceuticals, Inc.

Criteria

Inclusion Criteria:

• BMI >/= 25 to
• Type 2 Diabetes Mellitus and on a stable dose of metformin

• Hypertriglyceridemia

Exclusion Criteria:

• Significant abnormalities in medical history, clinical examination or clinical testing

• Use of oral anti-diabetic medication other than metformin within 3 months prior to dosing

• History of outpatient insulin use for more than 2 weeks in the last year